$26.83
1.00% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US14843C1053
Symbol
CSTL

Castle Biosciences Inc Stock price

$26.83
-3.61 11.86% 1M
+5.67 26.80% 6M
+5.25 24.33% YTD
+4.70 21.24% 1Y
-14.76 35.49% 3Y
-7.16 21.07% 5Y
+5.43 25.37% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.27 1.00%
ISIN
US14843C1053
Symbol
CSTL
Sector

Key metrics

Market capitalization $751.44m
Enterprise Value $498.39m
P/E (TTM) P/E ratio 134.22
EV/FCF (TTM) EV/FCF 12.45
EV/Sales (TTM) EV/Sales 1.60
P/S ratio (TTM) P/S ratio 2.41
P/B ratio (TTM) P/B ratio 1.70
Revenue growth (TTM) Revenue growth 62.43%
Revenue (TTM) Revenue $311.88m
EBIT (operating result TTM) EBIT $-1.04m
Free Cash Flow (TTM) Free Cash Flow $40.03m
Cash position $279.79m
EPS (TTM) EPS $0.20
P/E forward 73.65
P/S forward 2.31
EV/Sales forward 1.53
Short interest 6.77%
Show more

Is Castle Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Castle Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Castle Biosciences Inc forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Castle Biosciences Inc forecast:

Buy
100%

Financial data from Castle Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
312 312
62% 62%
100%
- Direct Costs 67 67
28% 28%
22%
245 245
75% 75%
78%
- Selling and Administrative Expenses 180 180
11% 11%
58%
- Research and Development Expense 53 53
2% 2%
17%
12 12
117% 117%
4%
- Depreciation and Amortization 13 13
13% 13%
4%
EBIT (Operating Income) EBIT -1.04 -1.04
99% 99%
0%
Net Profit 6.08 6.08
108% 108%
2%

In millions USD.

Don't miss a Thing! We will send you all news about Castle Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Castle Biosciences Inc Stock News

Neutral
Business Wire
6 days ago
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle today provided an update on its test currently in development for use in patients diagnosed with moderate-to-severe atopic dermatitis.
Neutral
Business Wire
10 days ago
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CastleBiosciences--Castle's Compensation Committee of its Board of Directors granted restricted stock units (RSUs) as inducement material to new employees.
Neutral
Business Wire
17 days ago
FRIENDSWOOD, Texas--(BUSINESS WIRE)---- $CSTL #CSTL--Meta-analysis concludes DecisionDx-Melanoma provides improved risk stratification over staging alone to inform personalized management of melanoma.
More Castle Biosciences Inc News

Company Profile

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, which is a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Head office United States
CEO Derek Maetzold
Employees 610
Founded 2007
Website www.castlebiosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today